158 related articles for article (PubMed ID: 21845536)
21. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
22. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
[TBL] [Abstract][Full Text] [Related]
23. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
25. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
26. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
[TBL] [Abstract][Full Text] [Related]
27. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
28. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
[TBL] [Abstract][Full Text] [Related]
29. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
[TBL] [Abstract][Full Text] [Related]
30. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
31. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
34. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
35. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
[TBL] [Abstract][Full Text] [Related]
36. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
[TBL] [Abstract][Full Text] [Related]
37. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
38. The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.
Krigers A; Moser P; Fritsch H; Demetz M; Brawanski K; Thomé C; Freyschlag CF
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3003-3009. PubMed ID: 34173871
[TBL] [Abstract][Full Text] [Related]
39. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
[TBL] [Abstract][Full Text] [Related]
40. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
